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aBsTRacT
INTRODUCTION: Patients with head and neck squamous cell 
carcinoma (HNSCC) are at an elevated risk of developing 
second primary malignancies (SPM). Our objectives were to 
estimate the excess risk of oesophageal and gastric SPMs in 
patients with malignancies of the pharynx or larynx and, 
add itionally, to examine possible risk factors of developing 
SPMs. 
METHODS: Data on all patients treated for HNSCC with  
curative intent in the Region of Southern Denmark in the 
period between 1 January 2000 and 31 December 2010 
were reviewed. A total of 1,172 patients were identified. 
The combined data from the DAHANCA database, the Dan-
ish National Pathology Registry and the patient charts were 
analysed. 
RESULTS: A total of 27 patients developed a SPM in the oe-
sophagus or stomach corresponding to a standardised inci-
dence ratio of 9.5 (95% confidence interval (CI): 6.5-13.9). 
Supraglottic (odds ratio (OR) = 6.9; p < 0.004) and hypo-
pharyngeal (OR = 3.9; p < 0.049) index tumour sites were 
significant risk factors for developing SPM. The median sur-
vival of patients with SPM was 3.6 years (95% CI: 1.6-5.1; 
range: 0.7-12.4) from diagnosis of the index cancer com-
pared with 3.4 years (95% CI: 3.1-4.3; range: 0.04-13.7) for 
patients without SPM. 
CONCLUSION: In this study, we confirm that there is an ele-
vated risk of developing oesophageal and gastric cancer in 
the Danish population of patients with a cancer in the su-
praglottic or hypopharyngeal region. Therefore, we recom-
mend close follow-up of these patients and a low threshold 
for examination of the oesophagus and stomach. 
FUNDING: not relevant. 
TRIAL REGISTRATION: not relevant.
Several studies have shown an excess risk of second pri-
mary malignancies (SPMs) among patients with head 
and neck squamous cell carcinomas (HNSCCs). It is pos-
tulated that this is an important factor in explaining why 
these patients’ survival has not increased despite im-
provement in the treatment modalities [1, 2]. The ana-
tomic sites with elevated risk of SPM seem to be the 
head and neck, lungs and oesophagus. Diagnosing SPMs 
in the oesophagus is challenging as the symptoms mimic 
the side effects typically seen following radiation ther-
apy of malignancies in the head and neck region. There-
fore, SPMs of the oesophagus are rarely detected at an 
early stage despite intensive surveillance of these pa-
tients. 
It remains uncertain to what extent the combin-
ation of HNSCCs and oesophageal/gastric cancers is 
prevalent in the Danish population and how it affects 
survival. The overall five-year survival rate for patients 
with cancer of the pharynx and larynx is 25-50% and 
62%, respectively, compared with 11% for patients diag-
nosed with oesophageal cancer [3]. The presumed sur-
vival of the patients developing SPMs is lower, and rec-
ognition of these tumours at an early stage is likely to be 
of great importance for the prognosis [4, 5]. The risk fac-
tors for developing SPM are not clarified, but age, gen-
der, alcohol ingestion and anatomic site of the index 
cancer seem to be of importance [6, 7]. The aim of this 
study was to clarify the frequency of second primary  
oesophageal and gastric cancers in patients with malig-
nancies of the pharynx and larynx who have undergone 
treatment with curative intent in a geographically well-
defined cohort. Furthermore, patient characteristics 
with possible influence on the risk of developing SPM, as 
well as tumour type and TNM stage of the SPMs, were 
examined.
mEThOds
Data on all patients treated for HNSCC with curative in-
tent in the Region of Southern Denmark in the period 
between 1 January 2000 and 31 December 2010 were 
extracted from the Danish Head and Neck Cancer Group 
(DAHANCA) database. Patient characteristics, co-mor-
bidity and tumour stage have been registered consecu-
tively in the DAHANCA database since 1970, and this 
registration has been fully established nationwide since 
1991. The database correlates 96% with the Danish Can-
cer Registry, which aims to register all cancer cases in 
Denmark [8, 9].
To identify the patients with SPMs in the oesopha-
gus or stomach, the DAHANCA data were matched with 
data from the Danish National Pathology Registry 
(PATOBANK), which is a national database containing 
data from all pathology reports in Denmark. Second can-
cers include both synchronous (diagnosed within six 
months from HNSCC diagnosis) and metachronous oe-
sophageal and gastric cancers. This study does not dif-
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ferentiate between synchronous and metachronous 
SPMs. Thus, all patients with a Systematized Nomencla-
ture of Medicine (SNOMED) code representing oesopha-
geal or gastric topography as well as malignancy in the 
PATOBANK were matched with the DAHANCA database 
using the patient’s social security number. All malig-
nancies registered between 1 January 2000 and 31 
October 2013 were included. With this approach, only 
the histologically verified malignancies were examined, 
and patients who had moved to another region of 
Denmark were not lost during follow-up.
Patients in the study group underwent examination 
according to the national DAHANCA guidelines in which 
gastroscopy in not a routine procedure in suspected la-
ryngeal or pharyngeal cancer [10].
The information about diagnosis, co-morbidity, risk 
factors, TNM stage, treatment strategy, etc. was ob-
tained from the DAHANCA database and supplemented 
through patient chart reviews. Symptoms of SPMs were 
also registered. 
When calculating the incidence, the crude rate in 
the study population was not comparable with that of 
the general population because of the difference in dis-
tribution of age and gender in the two populations. 
Therefore, the standardised incidence ratio (SIR) was 
used. SIR was defined as the ratio between the observed 
and the expected number of patients with oesophageal 
and gastric cancer. The expected number was obtained 
by applying the age- and sex-specific incidence rates in 
Southern Denmark to the study population. The age- 
and gender-specific incidence rates were obtained from 
The Association of the Nordic Cancer Registries (ANCR), 
which unifies data from the Nordic national cancer regis-
tries [11, 12]. To match the study period, the incidence 
rates from 2000 to 2011 were used. The risk time, the 
number of person years at risk (PYR), in the patient 
groups was defined as the number of years from the 
date of the diagnosis of an index cancer to either the 
date of diagnosis of SPM, the date of death or the end of 
the study period.
To compare the risk factors, a control group was 
picked randomly from the patients not diagnosed with 
oesophageal or gastric cancer with a ratio of four con-
trols to one case.
Trial registration: not relevant.
statistics 
Data were recorded and analysed in STATA 13. 95% con-
fidence intervals (CIs) were calculated for the SIRs. Uni-
variate logistic regression (reporting ORs) and multivari-
ate logistic regression were performed to evaluate each 
risk factor. Survival was estimated by the Kaplan-Meier 
method including log-rank test for comparison of sur-
vival. For group comparison of the risk factors, we used 
the Cox proportional hazards model (hazard ratios with 
CIs). p < 0.05 was considered statistically significant.
REsUlTs
A total of 1,172 HNSCC patients were identified, and 27 
(2.3%) patients had an SPM. The SPM was diagnosed at 
a median age of 63.2 years (95% CI: 58.9-67.8; range: 
53.2-81.9) and with a median time interval of 23.0 
months (95% CI: 14.3-31.1; range: 4.0-146.0) after the 
diagnosis of the HNSCC. The cumulated rate of diag-
nosed SPMs is seen in Figure 1.
The combined data from the DAHANCA database 
and the PATOBANK identified four patient categories:  
1) oesophageal or gastric cancer as the second cancer, 
2) oesophageal or gastric cancer as the index cancer,  
3) HNSCC involving part of the oesophagus and 4) pa-
tients who underwent biopsy of the oesophagus with 
normal histology who simultaneously underwent biopsy 
of another location (i.e. the larynx or pharynx) with his-
tologically confirmed malignancy. Review of the patient 
charts of the latter group of patients showed no clinical 
signs of oesophageal cancer and they were therefore ex-
cluded. Only the patients from the first group were in-
cluded in this study. 
symptoms, diagnosis and treatment  
of second primary malignancies
A large number of the patients developing SPM experi-
enced persistent, increasing or new-onset dysphagia, 
haematemesis, epigastric pain or painful swallowing 
during the period from completing radiotherapy to the 
diagnosis of the SPM. Of these 27 patients, 17 (63%) had 
consulted a doctor > 2 months before the SPM was diag-
nosed as they experienced at least one of the symp-
FigURE 1
Kaplan-Meier plot of cumulated rate of diagnosed second primary  
malignancies.
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toms. Of these, seven were seen by the doctor > 6 
months before the SPM was diagnosed. During this  
period, oesophagoscopy was performed in eight of the 
17 patients; and in four patients, a narrowing of the oe-
sophagus was recognised at the tumuor site, but initially 
considered to be benign. 
In the population studied, curative treatment of the 
SPM was initiated in five (18.5%) patients while the ma-
jority had no or only palliative treatment. Tumour char-
acteristics of the SPMs are shown in Table 1. Few pa-
tients were candidates for therapy and many did not 
complete the full examination programme. Therefore, 
the registration of TNM stage of the SPM in the patient 
charts was incomplete in several cases. The anatomic lo-
cation of the SPM was the proximal third in six (22.2%) 
patients, the middle third in five (18.5%) patients and 
the distal third of the oesophagus in ten (37.0%) pa-
tients, while six (22.2%) of the SPMs were located to the 
stomach. 
standardised incidence ratio for  
second primary malignancies
The ratio of oesophageal and gastric cancer not adjusted 
for age, gender or time at risk was 2.3%. The 27 SPMs 
were observed over 5,610 PYR. Using the age- and gen-
der-specific incidence rates, calculated with data from 
ANCR, the expected number of SPMs would be 2.8 [12]. 
Therefore, the SIR for oesophageal and gastric cancer 
was 9.5 (95% CI: 6.5-13.9) compared with the general 
population of the Region of Southern Denmark. 
Risk factors for developing  
second primary malignancies
Patient demographics and risk factors (gender, age at 
HNSCC diagnosis, body mass index at HNSCC diagnosis, 
smoking status, index tumour site, Union for Interna-
tional Cancer Control (UICC, 2010) stage and TNM stage 
of the index cancer) were initially analysed by univariate 
analysis. The site of the index tumour had a significant 
influence on the development of SPM. The patients with 
supraglottic index tumours had the highest risk of SPM 
compared with index tumours located in the oropharynx 
(OR = 6.9; p < 0.004). In addition, patients with hypo-
pharyngeal index tumours were at increased risk (OR = 
3.9; p < 0.049) of developing a SPM. However, a multi-
variate analysis did not reveal any different significant 
results.
survival analysis 
The median survival was 3.6 years (95% CI: 1.6-5.1; 
range: 0.7-12.4) for patients developing a SPM and 3.4 
years (95% CI: 3.1-4.3; range: 0.04-13.7) for patients not 
developing SPM. When comparing the two median  
values, we found no statistically significant difference. 
Median survival from diagnosis of SPM was 5.0 months 
(95% CI: 0.7-10.3; range: 0.0-41.1). The survival curves 
for patients with and without SPM are shown in Figure 
2. When analysing the factors with impact on the sur-
vival of the patients; weight (hazard ratio (HR) = 0.98; 
95% CI: 0.96-0.99; p < 0.009), age at diagnosis (HR = 
1.02; 95% CI: 1.00-1.05; p < 0.050), and N-stage of the 
index cancer (HR = 1.38; 95% CI: 1.09-1.75; p < 0.008) 
were identified as significant predictors of survival.
discUssiOn
This case-control and retrospective cohort study based 
on the population of Southern Denmark confirmed an 
increased risk of developing oesophageal or gastric can-
cer following HNSCC, supporting the theory of an associ-
ation between these cancer types. 
Surprisingly, the odds for developing oesophageal 
or gastric cancer among patients with an index cancer 
located in the supraglottic part of larynx were signifi-
cantly higher than in patients with an index cancer lo-
TaBlE 1
Tumour characteristics of the second primary malignancies.
 Frequency %
T-stage   
1   3 11.1
2   4 14.8
3   7 25.9
4   1   3.7
No data 12 44.4
N-stage   
0   7 25.9
1   9 33.3
No data 11 40.7
M-stage      
0 15 55.6
1   4 14.8
No data   8 29.6
Treatment   
None 10 37.0
Palliative therapy 11 40.7
Chemotherapy with curative intent   5 18.5
Other   1   3.7
Age at diagnosis, yrs   
50-60 11 40.7
60-70 11 40.7
> 70   5 18.5
Cancer site   
Proximal 3rd   6 22.2
Middle 3rd   5 18.5
Distal 3rd 10 37.0
Cardia and stomach   6 22.2
Histology   
Squamous cell carcinoma 18 69.2
Adenocarcinoma   8 30.8
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cated in the oropharynx. Previous studies found that  
tumours tend to follow either a respiratory (larynx-lung) 
or digestive (pharynx-esophagus) axis [1, 6, 13]. This di-
vergence could possibly be explained by the increasing 
number of human papillomavirus (HPV)-associated oro-
pharyngeal malignancies in the past decade. For the  
period from 1975 to 2006, Morris et al [14] found that 
the risk of SPM of the oesophagus significantly decre-
ased in patients with oropharyngeal cancer, but in-
creased in patients with cancer in the larynx, although 
this was not statistically significant. Unfortunately, in our 
study it was not possible to analyse how the HPV influ-
ences the risk of SPM, since HPV status registration in 
the DAHANCA database only started recently. However, 
a recent study of the impact of index HNSCC tumour  
site on SPM risk [15] found that patients with an index 
HNSCC of the oropharynx and a typical HPV phenotype 
had a very low SPM rate.
We found no significant difference in survival be-
tween patients with and without SPM. This may be due 
to the overall excess mortality among head and neck 
cancer patients [16] and the fact that the non-SPM 
group had several competing causes of death [17], e.g. 
HNSCC, SPM of the lung and cardiovascular disease. 
Recent studies show a six-fold higher overall mortality 
risk in patients with cancer of the oral cavity and oro-
pharynx compared with the general population, mainly 
due to alcohol- and tobacco-associated diseases [18]. 
However, we found no significant difference between 
the two groups in the distribution of the analysed risk 
factors. Another explanation may be that patients devel-
oping SPMs have to survive long enough for the SPM to 
develop, which would mean that SPM may be an indir-
ect positive prognostic factor [19]. In the present study, 
the median interval from diagnosis of the index cancer 
to diagnosis of the SPM was 23 months, partly support-
ing this hypothesis. 
This study has some limitations. The retrospective 
design forced us to rely on the accuracy of the data-
bases, and the possibility that some SPMs were misclas-
sified as metastases or recurrences exists, particularly 
for malignancies in the upper third of the oesophagus. 
We aimed to minimise this by reviewing the charts of all 
patients who underwent biopsy of the oesophagus sim-
ultaneously with having a tumour classified as HNSCC. 
Besides misclassification, it is possible that we under-
estimated the number of patients developing a SPM as 
some patients may have died before the biopsy or even 
before recognition of the oesophageal or gastric cancer. 
Furthermore, it is noteworthy that the patients who 
were diagnosed with HNSCC in the late phase of the 
study (2010) were followed for less than three years and 
therefore just exceeded the mean time from diagnosis 
of the index cancer to diagnosis of the SPM possibly 
leading to further underestimation of SPMs. Ideally, the 
study should have had an even longer follow-up time. 
The strengths of the study, on the other hand, are  
the inclusion of all patients treated in the Region of 
Southern Denmark, which is an area that is representa-
tive of the whole Danish population, the high quality 
control of the DAHANCA database, the completeness of 
the PATOBANK database and the completeness of the 
follow-up data.
cOnclUsiOn
Based on a geographically well-defined cohort from the 
Danish population our study confirms that patients with 
an HNSCC are at an elevated risk of developing oesopha-
geal and gastric cancer, and it shows that these second 
primary tumours represent a threat to the patients who 
survive the HNSCC. Our data and several published  
studies support that this excess risk justifies close fol-
low-up of these patients and a low threshold for exam-
ination of the oesophagus and stomach.
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